Alnylam Pharmaceuticals, a biopharmaceutical company developing novel therapeutics based on RNA interference, has amended its two existing RNAi collaboration agreements with Merck and consolidated the efforts into a single ongoing collaboration.

Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34162§ionid=)